Madhya Pradesh Online Journal

Interstitial Lung Disease Pipeline Insight Report | 120+ Companies and 120+ Drugs

 Breaking News
  • No posts were found

Interstitial Lung Disease Pipeline Insight Report | 120+ Companies and 120+ Drugs

January 16
18:13 2023
Interstitial Lung Disease Pipeline Insight Report | 120+ Companies and 120+ Drugs

DelveInsight’s, “Interstitial Lung Diseases Pipeline Insight 2023” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Diseases pipeline drug profiles, including Interstitial Lung Diseases clinical trial and nonclinical stage products. It also covers the Interstitial Lung Diseases pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Interstitial Lung Diseases Pipeline Report

  • DelveInsight’s interstitial lung disease Pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for interstitial lung disease treatment.
  • The leading Interstitial Lung Diseases Companies include AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
  • Promising Interstitial Lung Diseases Pipeline Therapies include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280,  Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
  • The Interstitial Lung Diseases Companies and academics are working to assess challenges and seek opportunities that could influence R&D Interstitial Lung Disease. The Interstitial Lung Diseases pipeline therapies under development are focused on novel approaches to treat/improve Interstitial Lung Disease.

 

Discover the recent breakthroughs and advances in the interstitial lung disease drug treatment landscape @ Interstitial Lung Disease Pipeline Outlook

 

Recent Developmental Activities in the Interstitial Lung Disease Treatment Landscape

 

  • In March 2022, Blade Therapeutics, announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases. Cudetaxestat (BLD-0409), a non-competitive, reversible inhibitor of autotaxin, has demonstrated direct anti-fibrotic activity and differentiating preclinical and biochemical characteristics which support the potential for a treatment profile in lung and liver fibrosis. Cudetaxestat has been granted orphan drug designations in the treatment of IPF and systemic sclerosis.
  • In February 2022, Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF). BI 1015550 is an oral, phosphodiesterase 4B (PDE4B) inhibitor with the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function and inflammation associated with progressive fibrosing interstitial lung diseases (ILDs)
  • In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers
  • In January 2022, Horizon Therapeutics announced the first patient has enrolled in a Phase IIb pivotal trial to evaluate its development-stage medicine HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with IPF, the most common interstitial lung disease. HZN-825 is an oral selective LPAR1 antagonist that has shown early signs of clinical impact in systemic sclerosis. LPAR1 signaling has been implicated in fibrosis and inflammation, and preclinical and clinical evidence support the antifibrotic potential of LPAR1 antagonism across multiple organ systems, including both lung and skin.
  • In November 2021, Biotech Acquisition Company and Blade Therapeutics, Inc. entered into a definitive merger agreement. Upon the closing of the transaction, which is anticipated to occur in the first quarter of 2022, the combined company will be renamed Blade Biotherapeutics, Inc
  • In October 2021, Agomab Therapeutics announced that it entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders. 
  • In July 2021, FibroGen announced that FG-3019, the Company’s human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF)
  • In February 2021, ImmunoMet Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF) as well as granting it Orphan Drug Designation.

 

Interstitial Lung Disease Overview

Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue. The trigger can be a known agent that deposited within the lung tissues. In some cases, the fibrosis arises spontaneously.

 

Find out more about interstitial lung disease clinical trials and pipeline therapies @ Interstitial Lung Disease Treatment Landscape

 

Interstitial Lung Disease Emerging Drugs

 

DWN12088: Daewoong Pharmaceutical 

DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.

 

LYT-100: PureTech

LYT-100 is PureTech’s most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022. 

 

BMS-986278: Bristol-Myers Squibb

BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.

 

Interstitial Lung Disease Therapeutic Assessment

There are approx. 120+ key companies which are developing the therapies Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer.

 

Learn more about the novel and emerging interstitial lung disease therapies @ Interstitial Lung Disease Ongoing Clinical Trials Analysis

 

Interstitial Lung Disease Segmentation

The Interstitial Lung Disease Pipeline report proffers an integral view of the interstitial lung disease emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Scope of the Interstitial Lung Disease Pipeline Report

  • Coverage- Global
  • Interstitial Lung Disease Companies- AdAlta, Bristol-Myers Squibb, aTyr Pharma, Avalyn Pharmaceuticals, Beijing Continent Pharmaceutical, Regend Therapeutics, Reata Pharmaceuticals, FibroGen, PureTech Health, Bellerophon Pulse Technologies, OncoArendi Therapeutics, LTT Bio-Pharma, EmphyCorp, Genentech, Cudetaxestat, Boehringer Ingelheim, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Bristol-Myers Squibb, Avalyn Pharma, PureTech Health, Roche, Ark Biosciences, Novartis, Lung Therapeutics, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics,  Kadmon Pharmaceuticals, GenKyoTex, Taiho Pharmaceutical,Syndax Pharmaceuticals, Metagone Biotech, Galecto Biotech, CSL Behring and AstraZeneca, and others.
  • Interstitial Lung Disease Pipeline Therapies- AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280,  Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation,  Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
  • Interstitial Lung Disease Segmentation: Phases, Molecule Type, Mechanism of Action, Product Type

 

Table of Content

  1. Introduction
  2. Interstitial Lung Disease Executive Summary
  3. Interstitial Lung Disease: Overview
  4. Interstitial Lung Disease Pipeline Therapeutics
  5. Interstitial Lung Disease Therapeutic Assessment
  6. Interstitial Lung Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RO-0220912: Roche
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Daratumumab: Janssen Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. BGB 16673: BeiGene
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Interstitial Lung Disease Key Companies
  21. Interstitial Lung Disease Key Products
  22. Interstitial Lung Disease- Unmet Needs
  23. Interstitial Lung Disease- Market Drivers and Barriers
  24. Interstitial Lung Disease- Future Perspectives and Conclusion
  25. Interstitial Lung Disease Analyst Views
  26. Interstitial Lung Disease Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Interstitial Lung Disease drugs?
  • How many Interstitial Lung Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Lung Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Lung Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interstitial Lung Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Dive deep into rich insights into new interstitial lung disease drugs, visit @ Interstitial Lung Disease Key Companies and Pipeline Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories